Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has received an order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, regarding the adjudication of stamp duty on the Scheme of Arrangement (Demerger) between Aarti Industries Ltd and Aarti Pharmalabs Ltd. The order levies a stamp duty of Rs. 25 Crores and a penalty of Rs. 59.50 Crores. The company believes it has a strong case and will challenge the order.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced the cessation of Senior Management Personnel, Shri G.M. Naidu, due to resignation, effective August 31, 2026.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has published newspaper advertisements for the dispatch of the Annual Report for the Financial Year 2025-26 and the Notice of the 7th Annual General Meeting, which will be held on September 22, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM.)

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, as per Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced its 7th Annual General Meeting (AGM) scheduled for September 22, 2026, through video conferencing. The company has also released its Annual Report for the Financial Year 2025-26, highlighting its growth strategy and expansion plans.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced its Annual Report for FY 2025-26, along with the Notice of the 7th Annual General Meeting (AGM) scheduled to be held on September 22, 2026. The report highlights the company's growth strategy, expanded manufacturing infrastructure, and deepening CDMO pipeline.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd announced its 7th Annual General Meeting through Video Conferencing/OAVM on September 22, 2026, with a record date of September 15, 2026, for payment of final dividend for FY 2025-26. Shareholders were requested to register their Email-Ids with their depository participants.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced a record date for payment of final dividend for FY 2025-26, with a dividend of ₹2.00 per equity share of ₹5/- each, subject to shareholder approval at the ensuing Annual General Meeting.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced its Q1 FY27 earnings, with a 42% YoY increase in revenue to INR535 crores, and a 40% YoY increase in EBITDA to INR133 crores. The company's profit after tax for the quarter was INR71 crores, a 49% YoY increase. The management highlighted the completion of expansion projects, including the debottlenecking of the steroid block at Unit 4, Tarapur, and the commercialization of additional capacity for Xanthine derivatives.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has uploaded the audio recording of its earnings conference call for the first quarter ended June 30, 2026, on its website.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has released its Q1 FY 2027 investor presentation, highlighting its 25+ years of pharmaceutical excellence, 220+ products, 500+ global clients, and 63+ patents filed. The company has a strong presence in the xanthine derivatives market, with a global market share of 15-20%. It has also received various certifications and approvals from regulatory bodies such as USFDA, EU GMP, and EDQM.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has published its unaudited financial results for the quarter ended June 30, 2026, in the Financial Express and Loksatta-Jansatta newspapers, as per Regulation 47 of SEBI's Listing Obligations and Disclosure Requirements.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has informed that Mr. Rajendra Vallabhaji Gogri, a non-executive director, will not seek re-appointment as a director of the company due to personal goals and other commitments.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has approved capacity addition for Development of Intermediate Block at an estimated capex of Rs.149 Crores, and reconstituted its Audit Committee, Corporate Social Responsibility Committee, and Stakeholders Relationship Committee.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced changes in its board of directors, including the appointment of Rashesh C. Gogri as Managing Director and Hetal Gogri Gala as Executive Director, effective October 1, 2026. The company has also approved capacity addition for the development of an intermediate block at an estimated capex of Rs.149 Crores.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, and has also approved changes in the designation of two directors, Rashesh C. Gogri and Hetal Gogri Gala, and has approved the reconstitution of the Audit Committee, Corporate Social Responsibility Committee, and Stakeholders Relationship Committee.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced the outcome of its board meeting held on August 07, 2026. The board has approved the unaudited financial results for the quarter ended June 30, 2026, and has also approved changes in the designation of two directors, Rashesh C. Gogri and Hetal Gogri Gala. Additionally, the board has approved capacity addition for the development of an intermediate block at an estimated capex of Rs.149 Crores and reconstituted the audit committee, corporate social responsibility committee, and stakeholders relationship committee.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has scheduled an earnings conference call for Monday, August 10, 2026, at 4:00 p.m. (IST) to discuss its Q1-FY27 financial results.

Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has scheduled a Board Meeting on August 07, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.